Freer Hall
Urbana, Illinois, 61801, United States
NCT Number: NCT03117127
In crossover trials, ten (N=10) young men (18-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after resistance exercise, participants will ingest stable isotope labeled whole eggs (18 g protein, 17 g fat) or egg whites (18 g protein, 0 g fat) cooked in scrambled form. Repeated blood and muscle biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid transporters, anabolic signaling and myofibrillar protein synthesis rates during the trials.
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Not applicable
Urbana, Illinois, 61801, United States
On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, a baseline breath sample will be collected for determination of 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into an antecubital vein for baseline blood sample collection (t=-210 min) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous infusion of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210 min) and maintained over the infusion trials. A second Teflon catheter willinserted into a heated dorsal hand vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples and will be collected every 30 or 60 min during the postabsorptive- and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10 repetitions at 80% of 10-RM for both leg press and leg extension exercise.
Immediately after completion of the exercise bout, participants will consume 3 whole eggs or an equivalent amount of protein from egg whites (t=0 min). Completion of the meal will mark the start of the postprandial phase (t=0 min) and additional muscle biopsies will be collected at t=120 and 300 min.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
Participants will ingestion whole eggs immediately after resistance exercise
Participants will ingestion whole eggs immediately after resistance exercise
Time frame: Postabsorptive for 3 hours, Postprandial for 5 hours
Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental beverages. This will allow us to assess the change from the postabsorptive to the postprandial period
Time frame: Baseline and at 2 and 5 hours after protein ingestion
Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 5 hr after the ingestion of the whole egg and egg whites
Time frame: 5 hour postprandial phase
Dietary derived leucine availability will be measured during the 5 h postprandial phase to compare the dietary-derived leucine availability after whole egg and egg white ingestion.
University of Illinois at Urbana-Champaign
Other
The Consumption of Whole Eggs Versus Egg Whites to Stimulate Postprandial Muscle Protein Synthesis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05774444
Behavior, Hypertrophy
Glasgow, United Kingdom
View Trial DetailsNCT05544955
Hypertrophy, Pathological Conditions, Anatomical
Arlington, Virginia, United States
View Trial DetailsNCT03572127
Hypertrophy, Pathological Conditions, Anatomical
Exeter, Devon, United Kingdom
View Trial DetailsNCT05576337
Hypertrophy, Pathological Conditions, Anatomical
Porto Alegre, Rio Grande do Sul, Brazil
View Trial Details